• Vaccine Name: 1(SOCS1)-silenced dentritic cell (DC) vaccines
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0007186
• Type: Dendritic Cell Vaccine
• Status: Research
• Preparation: To obtain SOCS1-silenced DCs, DCs derived from mouse bone marrow cells ex vivo were induced to differentiation in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, and then transduced with Len-SOCS1-shRNA or control Len-GFP lentiviruses. The SOCS1-silenced DCs were loaded by TRP2 peptide to prepare the DC vaccine, which was induced to mature by LPS. The DCs were analyzed by flow cytometry (FCM) for surface expressions of MHCII and CD86 and by real-time PCR for the expressions of SOCS1, IL-10 as well as IL-12p40. B16 or IL-10-silenced B16 (IL-10(-/-);) cells were inoculated into C57BL/6 mice (Wang et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Immune Response: SOCS1 expression in DCs was down-regulated by 80% after Len-SOCS1-shRNA lentivirus infection. In the DCs with down-regulated SOCS1 expression, the expressions of MHCII and CD86 increased a little, which did not differ significantly from the control DCs, and IL-10 level dropped and IL-12p40 went up significantly compared with the control DCs. This vaccine has been used in treatment of Melanoma. (Wang et al., 2013).